Senti Biosciences Holdings, Inc. (SNTI) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Senti Biosciences is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform. The company completed a holding company reorganization on April 24, 2026. As of the reporting date, the company has no approved products and has not generated revenue from product sales.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Collaboration Revenue | $33,000 | $0 |
| Net Loss | $(16,971,000) | $(28,845,000) |
| Net Loss Per Share (Basic & Diluted) | $(0.55) | $(1.59) |
| Cash and Cash Equivalents (End of Period) | $6,463,000 | $16,420,000 |
| Net Cash Used in Operating Activities | $(21,730,000) | $(27,123,000) |
| Accumulated Deficit | $(375,543,000) | $(358,572,000) |
| Total Liabilities | $36,506,000 | $45,634,000 |
Debt and Liquidity: In May 2026, the company issued $10.0 million in senior secured convertible notes to a related party (Celadon affiliate). As of June 30, 2026, the fair value of these notes was recorded at $4.0 million. The company holds $1.4 million in restricted cash, primarily for lease letters of credit.
Material Changes vs. Prior Period
- Reduced Net Loss: The net loss decreased by $11.9 million (41%) compared to the prior year period, primarily driven by a one-time $6.9 million gain on lease modification resulting from the restructuring of the Alameda facility lease.
- Operating Expenses: Research and Development (R&D) expenses decreased by $6.3 million to $13.0 million, largely due to reduced external services for the SENTI-202 program. General and Administrative (G&A) expenses decreased slightly by $0.9 million to $13.0 million.
- Sublease Income: GeneFab sublease income decreased by $2.2 million to $1.1 million due to the lease amendments reducing the subleased premises.
- Balance Sheet: Total assets decreased from $51.2 million to $33.1 million, reflecting a reduction in cash and lease-related assets following the lease modification and operating burn.
Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern. With $6.5 million in cash, the company may not be able to maintain operations starting as early as the fourth quarter of 2026 without additional funding.
- Proposed Merger: On July 14, 2026 (subsequent to the period end), the company entered into a Merger Agreement with an affiliate of its largest stockholder, Celadon Partners. The transaction involves a spin-off of the core business (including SENTI-202) into a private entity. Public shareholders would receive Contingent Value Rights (CVRs) with a potential aggregate payout of up to $60.0 million based on regulatory and sales milestones for SENTI-202.
- Post-Merger Strategy: If the merger closes, the public company will retain only early-stage programs (Rett Syndrome and TIL therapies) and will require significant additional capital to continue operations.
- Convertible Notes Risk: The $10.0 million in convertible notes mature on November 23, 2026. If not converted, the company must repay 200% of the principal ($20.0 million). Failure to repay could trigger default and foreclosure on company assets.
- Nasdaq Compliance: The company's stockholders' equity has fallen below the $2.5 million minimum requirement, and the market value of listed securities is below the $35 million threshold, creating a risk of delisting.
Investor Verification Checklist
- Merger Approval: Verify the status of the stockholder vote required to approve the Merger Agreement and the issuance of shares underlying the convertible notes.
- Liquidity Runway: Confirm the timeline for the remaining $2.0 million of "Additional Notes" funding from Celadon and the company's ability to raise capital post-merger.
- Debt Maturity: Assess the risk of the November 2026 maturity of the convertible notes and the likelihood of conversion versus cash repayment.
- Nasdaq Status: Monitor communications regarding the company's plan to regain compliance with Nasdaq listing standards (minimum equity and market value).
- CVR Milestones: Review the specific regulatory and sales milestones required to trigger the $60.0 million contingent value rights for shareholders.